杨森制药的厄达替尼在中国上市了吗？

(Erdafitinib) is a new drug for the treatment of adult urothelial cancer. The drug was jointly discovered by Astex Pharmaceuticals of the United States and Janssen Biotech, a subsidiary of the Johnson & Johnson Pharmaceutical Group, in June 2008. Astex Pharmaceuticals authorized Janssen Biotech to develop and commercialize inhibitors emerging from FGFR research projects globally. Xi'an Janssen Pharmaceutical Co., Ltd., as the largest subsidiary of Johnson & Johnson in China, was established in 1985. It is headquartered in Beijing and has a production base in Xi'an. It has more than 5,000 employees in China.

As early as 2005, the American pharmaceutical company Astex had collaborated with the UK Cancer Research Drug Discovery Group and Cancer Research Technology Co., Ltd. at the University of Newcastle (Newcastle) in the UK to start a research plan for FGFR inhibitors. In March 2018, the U.S. Food and Drug Administration (FDA) granted erdafitinib Breakthrough Therapy Designation for the treatment of urothelial cancer.

On April 12, 2019, the FDA announced accelerated approval of erdafitinib, a tablet branded under the trade name Balversa®, for the treatment of adult patients with locally advanced or metastatic urothelial cancer whose disease has progressed despite platinum-based chemotherapy. This is the first FDA-approved targeted therapy for metastatic urothelial cancer. The successful launch of Erdafitinib has undoubtedly brought new options and opportunities for the treatment of many patients.

However, it is regrettable that Janssen Pharmaceuticals has not yet been approved by the National Medical Products Administration (NMPA) for domestic marketing in China. Therefore, patients in need can only purchase drugs overseas to meet their actual treatment needs. When purchasing medicine, patients can contact Medical Companion Travel.

Recommended hot articles: /newsDetail/96447.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.